Reports Q4 revenue $65M, consensus $63.93M. “The Company executed exceptionally well in 2023 and delivered outstanding financial and business results in the fourth quarter, generating top-tier revenue growth and even higher growth in our profitability metrics,” said Nick Colangelo, President and CEO of Vericel. “We expect that the momentum in our core portfolio and new product launches across our MACI and Burn Care commercial franchises will drive continued strong revenue growth and profitability in 2024 and the years ahead.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VCEL:
- Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
- Is VCEL a Buy, Before Earnings?
- Vericel price target raised to $53 from $49 at BTIG
- Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
